Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared. One share of VRTX stock can currently be purchased for approximately $214.33. There are currently 4 hold ratings, 21 buy ratings and 1 strong buy rating for the stock. Should You Take Comfort From Insider Transactions At Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)? Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. ... the average rating for VRTX stock is "Buy." Vertex Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Learn more. Vertex Pharmaceuticals has a P/B Ratio of 9.06. Devel. Do Not Sell My Information. Is Vertex Pharmaceuticals (VRTX) Stock a Buy For 2021? Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle, and Yuchun Lee. Vertex Energy Inc () Stock Market info Recommendations: Buy or sell Vertex Energy stock? MarketBeat just released five new trading ideas, but Vertex Pharmaceuticals wasn't one of them. 6:18am / MotleyFool.com - Paid Partner Content, Mar 11 / MotleyFool.com - Paid Partner Content, 5:51am / MotleyFool.com - Paid Partner Content, Mar 11 / Zacks.com - Paid Partner Content, Mar 12 / MotleyFool.com - Paid Partner Content, Mar 09 / Zacks.com - Paid Partner Content, Mar 07 / MotleyFool.com - Paid Partner Content, Mar 03 / Zacks.com - Paid Partner Content, This Underperforming Biotech Is Ready to Beat the Market, 5 Disruptive Stocks to Buy for a Biden Bull Market, Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins, 2 Stocks Cathie Wood Loves That Should Be Bigger Winners Than Tesla, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know, Forget GameStop, AMC, and Sundial: These Are the Best Stocks to Buy Right Now, bluebird (BLUE) Up on Updated Findings in LentiGlobin's SCD Study. Menu. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. You may vote once every thirty days. © American Consumer News, LLC dba MarketBeat® 2010-2021. Vertex Pharmaceuticals has a PEG Ratio of 1.25. CNN Sans™ & © 2016 Cable News Network. View analyst ratings for Vertex Pharmaceuticals or view top-rated stocks. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees. VP of Global Research & Chief Scientific Officer, Exec. The P/E ratio of Vertex Pharmaceuticals is 27.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 32.68. Specifically, they have bought $0.00 in company stock and sold $1,172,012.00 in company stock. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Vertex Pharmaceuticals' stock is owned by a variety of retail and institutional investors. View which stocks have been most impacted by COVID-19. Since then, VRTX shares have decreased by 2.7% and is now trading at $214.33. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]. ), Vertex Pharmaceuticals has received 807 “underperform” votes. Get the latest Vertex Pharmaceuticals (VRTX) stock price quote with real-time news, financials, charts and other important investing information. Is Vertex a Great Value Stock to Add to Your Portfolio? View VRTX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. VP & Chief Admin., Legal and Bus. Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX.". Wall Street Stock Market & Finance report, prediction for the future: You'll find the Vertex Energy share forecasts, stock quote and buy / sell signals below.According to present data Vertex … What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash? There are mixed signals in the stock today. Real time Vertex Pharmaceuticals (VRTX) stock price quote, stock graph, news & analysis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex (VRTX) Down 2.4% Since Last Earnings Report: Can It Rebound? Learn everything you need to know about successful options trading with this three-part video course. Export data to Excel for your own analysis. Receive a free world-class investing education from MarketBeat. April 23rd Options Now Available For Vertex Pharmaceuticals (VRTX). Their forecasts range from $250.00 to $347.00. Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee. Exec. S&P 500 3,943.34 Vote “Outperform” if you believe VRTX will outperform the S&P 500 over the long term. Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Factset: FactSet Research Systems Inc.2019. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. See what's happening in the market right now with MarketBeat's real-time news feed. The 12-month stock price forecast … Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Vertex Pharmaceuticals does not currently pay a dividend. Best Biotech Stocks To Buy Right Now? Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. It’s an Opportunity for Investors. Shares buyback plans are often a sign that the company's board believes its stock is undervalued. What is VRTX's earnings growth forecast for 2021-2023? Vertex Pharmaceuticals' management team includes the following people: A terrifying (for some) and new disruptive force is creating thousands of new millionaires (Barron’s reports 20,000 to 200,000 so far) while at the same time destroying the financial future for many others. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. VRTX stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Janus Henderson Group PLC, Alliancebernstein L.P., Assenagon Asset Management S.A., UBS Asset Management Americas Inc., Swedbank, Amundi Pioneer Asset Management Inc., and Amundi Pioneer Asset Management Inc.. View insider buying and selling activity for Vertex Pharmaceuticals or or view top insider-buying stocks. Over the next 52 weeks, Vertex Pharmaceuticals Inc has on average historically risen by 29.7 % based on the past 29 years of stock performance. Skip to content. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Please log in to your account or sign up in order to add this asset to your watchlist. All rights reserved. Compare Top Brokerages Here. Officer, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, Spain: Police bust major drug distribution network in Madrid, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Interesting VRTX Put And Call Options For April 30th, Vertex to begin Phase 1/2 trial of treatment for people with type 1 diabetes, Vertex Reports FDA Fast Track Designation For VX-880 - Quick Facts, Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes, 5 Stocks to Watch Amid Continued Expansion in the Biotech Industry, Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis. Vertex Pharmaceuticals stock price predictions Our Accessibility Statement Sign-up to receive the latest news and ratings for VRTX and its competitors with MarketBeat's FREE daily newsletter. View Vertex Pharmaceuticals Incorporated VRTX investment & stock information. Vertex Stock Fell After a Setback on a New Drug. Vertex Pharmaceuticals has received 64.31% “outperform” votes from our community. All rights reserved. 31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Get the latest Vertex Pharmaceuticals Incorporated VRTX detailed stock quotes, stock data, Real-Time ECN, … Vertex Energy. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Vertex to Present at the Cowen Health Care Conference on March 2, Interesting VRTX Put And Call Options For May 21st. The consensus among Wall Street analysts is that investors should "buy" Vertex Pharmaceuticals stock. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Fall Y/Y, 5 Sizzling Growth Stocks to Buy for a Biden Bull Market. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View our full suite of financial calendars and market data tables, all for free. In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. 26 equities research analysts have issued twelve-month price objectives for Vertex Pharmaceuticals' stock. View insider buying and selling activity for Vertex Pharmaceuticals or view top insider-selling stocks. The Vertex Energy stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. All Rights Reserved. The pharmaceutical company reported $2.51 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.59 by $0.08. Looking for new stock ideas? See Vertex Pharmaceuticals Incorpor (VRTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Some companies that are related to Vertex Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210. View all of VRTX's competitors. VRTX stock forecast Our latest prediction for Vertex Pharmaceuticals, Inc.'s stock price was made on the July 10, 2020 when the stock price was at 294.45$.. Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Vertex Pharmaceuticals has a market capitalization of $55.72 billion and generates $4.16 billion in revenue each year. A high-level overview of Vertex Pharmaceuticals Incorporated (VRTX) stock. Get short term trading ideas from the MarketBeat Idea Engine. Vertex Pharmaceuticals employs 3,000 workers across the globe. Earnings for Vertex Pharmaceuticals are expected to grow by 9.29% in the coming year, from $8.50 to $9.29 per share. View which stocks are hot on social media with MarketBeat's trending stocks report.